|
Telomolecular nanotechnologies have been shown to regenerate human tissues. The corporation's primary focus
is on the delivery of therapeutic agents that lengthen and repair
chromosomal telomeres in living animals. Successful therapies based on this tactic may
offset, and potentially reverse, many devastating age-related diseases and perhaps
address the symptoms and signs recognized as human aging.
Management intends to focus on the acquisition of patents and technologies that are potentially useful
in treating specific diseases in targeted ways. A less stated but obvious goal is
addressing (generically) fundamental human aging.
|
